Prognostic significance of lymphocyte patterns in multiple myeloma patients after autologous transplant

被引:4
|
作者
Stork, Martin [1 ]
Bezdekova, Renata [2 ]
Kralova, Romana [2 ]
Sandecka, Viera [1 ]
Adam, Zdenek [1 ]
Krejci, Marta [1 ]
Boichuk, Ivanna [1 ]
Knechtova, Zdenka [1 ]
Brozova, Lucie [3 ]
Sevcikova, Sabina [4 ]
Rihova, Lucie [2 ]
Pour, Ludek [1 ]
机构
[1] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic
[2] Univ Hosp Brno, Dept Clin Hematol, Brno, Czech Republic
[3] Inst Biostat & Anal Ltd, Brno, Czech Republic
[4] Masaryk Univ, Fac Med, Dept Pathophysiol, Babak Myeloma Grp, Brno, Czech Republic
关键词
multiple myeloma; minimal residual disease; lymphocyte; flow cytometry; MINIMAL RESIDUAL DISEASE; PERIPHERAL-BLOOD; BONE-MARROW; CELLS; SURVIVAL; PROGRESSION; SUBSETS; THERAPY; IMPACT; NKT;
D O I
10.4149/neo_2021_200814N861
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite the high efficacy of current induction regimens, most multiple myeloma (MM) patients relapse over time. The link between changes in the immune system and the prognosis of the disease is still not entirely clear. Therefore, we analyzed whether the pattern of bone marrow (BM) lymphocytes during routine BM examination after autologous stem cell transplant (ASCT) is related to disease prognosis or MRD negative complete remission. From 2009 to 2018, 98 MM patients underwent routine BM testing after the first ASCT. Using multi-parametric flow cytometry, twelve BM lymphocyte subtypes were analyzed. In 60% of patients who achieved a complete response (CR), MRD by flow cytometric analysis (sensitivity threshold 10-6) was evaluated. We found an association of relative proportion of BM lymphocyte subtypes with treatment response, progression-free survival (PFS), overall survival (OS), and minimal residual disease (MRD) negativity. Higher relative proportion of memory B cells was associated with inferior median PFS [HR 1.089 (95% CI: 1.023-1.160), p=0.0081 and median OS [HR 1.170 (95% CI: 1.074-1.274), p<0.001]. In non-responding patients (minimal response and worse), higher proportion of memory B cells was found when compared to patients achieving CR [3.8% (range 0.5-35.0) vs. 1.0% (range 0.1-12.5); p=0.0011. No significant association of BM lymphocyte subtypes proportion with MRD negative CR was found. Our results show that changes in BM lymphocyte subsets including memory B cells may have prognostic value in MM patients after ASCT.
引用
收藏
页码:519 / 527
页数:9
相关论文
共 50 条
  • [31] Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma
    Christopher Lemieux
    Lori S. Muffly
    David J. Iberri
    Juliana K. Craig
    Laura J. Johnston
    Robert Lowsky
    Parveen Shiraz
    Andrew R. Rezvani
    Matthew J. Frank
    Wen-Kai Weng
    Everett Meyer
    Judith A. Shizuru
    Sally Arai
    Michaela Liedtke
    Robert S. Negrin
    David B. Miklos
    Surbhi Sidana
    Bone Marrow Transplantation, 2021, 56 : 2664 - 2671
  • [32] Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant
    Holstein, Sarah A.
    Richardson, Paul G.
    Laubach, Jacob P.
    McCarthy, Philip L.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (05) : 793 - 798
  • [33] Changes in Laboratory Indexes for Multiple Myeloma Patients Before and After Autologous Stem Cell Transplant
    Zhao, Rui
    Zhao, Jing
    Song, Yichuan
    Fu, Wenxuan
    Wang, Qingtao
    Zhang, Rui
    JOURNAL OF INFLAMMATION RESEARCH, 2023, 16 : 5779 - 5789
  • [34] Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma
    Lemieux, Christopher
    Muffly, Lori S.
    Iberri, David J.
    Craig, Juliana K.
    Johnston, Laura J.
    Lowsky, Robert
    Shiraz, Parveen
    Rezvani, Andrew R.
    Frank, Matthew J.
    Weng, Wen-Kai
    Meyer, Everett
    Shizuru, Judith A.
    Arai, Sally
    Liedtke, Michaela
    Negrin, Robert S.
    Miklos, David B.
    Sidana, Surbhi
    BONE MARROW TRANSPLANTATION, 2021, 56 (11) : 2664 - 2671
  • [35] Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant
    Sasaki, Koji
    Shah, Nina
    Bashir, Qaiser
    Hosing, Chitra M.
    Popat, Uday R.
    Nieto, Yago
    Parmar, Simrit
    Shah, Jatin J.
    Weber, Donna
    Weissinger, Daniel
    Thomas, Sheeba K.
    Orlowski, Robert Z.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BLOOD, 2015, 126 (23)
  • [36] PROGNOSTIC SIGNIFICANCE OF BEHAVIORAL SYMPTOMS FOR MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
    Costanzo, Erin S.
    Rumble, Meredith E.
    Juckett, Mark B.
    Coe, Christopher L.
    Hematti, Peiman
    Callander, Natalie S.
    PSYCHOSOMATIC MEDICINE, 2018, 80 (03): : A83 - A83
  • [37] BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma
    Talamo, G.
    Claxton, D. F.
    Dougherty, D. W.
    Ehmann, C. W.
    Sivik, J.
    Drabick, J. J.
    Rybka, W.
    BONE MARROW TRANSPLANTATION, 2009, 44 (03) : 157 - 161
  • [38] Melphalan-based autologous transplant in octogenarian multiple myeloma patients
    Saini, Neeraj Y.
    Patel, Romil
    Varma, Ankur
    Bashir, Qaiser
    Delgado, Ruby
    Rondon, Gabriela
    Popat, Uday R.
    Hosing, Chitra M.
    Nieto, Yago
    Kebriaei, Partow
    Alousi, Amin M.
    Ahmed, Sairah
    Weber, Donna M.
    Thomas, Sheeba K.
    Lee, Hans C.
    Manasanch, Elisabet E.
    Patel, Krina K.
    Orlowski, Robert Z.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (01) : E2 - E5
  • [39] Management of patients with an autologous transplant option in newly diagnosed multiple myeloma
    Goldschmidt, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 8 - 8
  • [40] BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma
    G Talamo
    D F Claxton
    D W Dougherty
    C W Ehmann
    J Sivik
    J J Drabick
    W Rybka
    Bone Marrow Transplantation, 2009, 44 : 157 - 161